Agenus Inc. (AGEN)

Market Cap	152.49M
Revenue (ttm)	156.31M
Net Income (ttm)	-245.97M
Shares Out	20.95M
EPS (ttm)	-13.80
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	873,297
Open	6.84
Previous Close	6.46
Day's Range	6.31 - 7.45
52-Week Range	4.78 - 42.60
Beta	1.28
Analysts	Strong Buy
Price Target	146.50 (+1,898.64%)
Earnings Date	May 7, 2024

About AGEN

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 4, 2000
• Employees: 389
• Stock Exchange: NASDAQ
• Ticker Symbol: AGEN

Financial Performance

In 2023, Agenus's revenue was $156.31 million, an increase of 59.47% compared to the previous year's $98.02 million. Losses were -$245.97 million, 11.7% more than in 2022.

Analyst Forecast

According to 4 analysts, the average rating for AGEN stock is "Strong Buy." The 12-month stock price forecast is $146.5, which is an increase of 1,898.64% from the latest price.

Price Target

$146.5

(1,898.64% upside)

Analyst Consensus: Strong Buy